These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19633042)

  • 1. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
    Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A
    Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
    Schmidt M; Rüttinger D; Sebastian M; Hanusch CA; Marschner N; Baeuerle PA; Wolf A; Göppel G; Oruzio D; Schlimok G; Steger GG; Wolf C; Eiermann W; Lang A; Schuler M
    Ann Oncol; 2012 Sep; 23(9):2306-2313. PubMed ID: 22357251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
    Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
    Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
    Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
    Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.
    Kurtz JE; Dufour P
    Expert Opin Biol Ther; 2010 Jun; 10(6):951-8. PubMed ID: 20426706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
    Oberneder R; Weckermann D; Ebner B; Quadt C; Kirchinger P; Raum T; Locher M; Prang N; Baeuerle PA; Leo E
    Eur J Cancer; 2006 Oct; 42(15):2530-8. PubMed ID: 16930989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.
    Kirman I; Whelan RL
    Curr Opin Mol Ther; 2007 Apr; 9(2):190-6. PubMed ID: 17458174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.
    Eyvazi S; Farajnia S; Dastmalchi S; Kanipour F; Zarredar H; Bandehpour M
    Curr Cancer Drug Targets; 2018; 18(9):857-868. PubMed ID: 29295696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
    Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo H; Sledge G; Koehler M; Ellis C; Casey M; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2010 Mar; 28(7):1124-30. PubMed ID: 20124187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
    Münz M; Murr A; Kvesic M; Rau D; Mangold S; Pflanz S; Lumsden J; Volkland J; Fagerberg J; Riethmüller G; Rüttinger D; Kufer P; Baeuerle PA; Raum T
    Cancer Cell Int; 2010 Nov; 10():44. PubMed ID: 21044305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
    Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
    Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
    Goel S; Bauer RJ; Desai K; Bulgaru A; Iqbal T; Strachan BK; Kim G; Kaubisch A; Vanhove GF; Goldberg G; Mani S
    Ann Oncol; 2007 Oct; 18(10):1704-7. PubMed ID: 17693421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.